All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease.
Acta Diabetol
; 58(10): 1425-1428, 2021 Oct.
Article
en En
| MEDLINE
| ID: mdl-34050821
ABSTRACT
AIMS:
The rate of all-cause mortality is twofold higher in type 2 diabetes than in the general population. Being able to identify patients with the highest risk from the very beginning of the disease would help tackle this burden.METHODS:
We tested whether ENFORCE, an established prediction model of all-cause mortality in type 2 diabetes, performs well also in two independent samples of patients with early-stage disease prospectively followed up.RESULTS:
ENFORCE's survival C-statistic was 0.81 (95%CI 0.72-0.89) and 0.78 (95%CI 0.68-0.87) in both samples. Calibration was also good. Very similar results were obtained with RECODe, an alternative prediction model of all-cause mortality in type 2 diabetes.CONCLUSIONS:
In conclusion, our data show that two well-established prediction models of all-cause mortality in type 2 diabetes can also be successfully applied in the early stage of the disease, thus becoming powerful tools for educated and timely prevention strategies for high-risk patients.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
6_ODS3_enfermedades_notrasmisibles
Problema de salud:
6_diabetes
/
6_endocrine_disorders
Asunto principal:
Diabetes Mellitus Tipo 2
Tipo de estudio:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Acta Diabetol
Asunto de la revista:
ENDOCRINOLOGIA
Año:
2021
Tipo del documento:
Article
País de afiliación:
Italia